MPLT Stock Plunges 73% — Wipes Out Over $1B In Market Cap After Trial Miss On Once-Daily Dose

MapLight's ML-007C-MA missed primary endpoint in mid-stage ZEPHYR trial.

Trial tested once-daily dose in 307 adults with acute schizophrenia worsening.

MPLT stock dropped 73%, erasing over $1 billion in market cap.

Adverse events observed but details not fully disclosed.